Editor,

A 39-year-old male with a renal transplant was admitted to hospital with abdominal pain and vomiting. A computed tomography (CT) scan of abdomen showed ischaemic large bowel. He proceeded to a laparotomy with ileocaecal resection and right hemicolectomy. 2 days later he had worsening abdominal pain and a repeat CT abdomen demonstrated ischaemic small bowel. He had a further laparotomy, small bowel resection and end ileostomy, leaving only 1 metre of small bowel distal to the duodenal-jejunal flexure. 12 days later there was recurrence of small bowel ischaemia and a further 20cm of distal ileum was removed, leaving only 80cm of small bowel. Initial post-operative immunosuppression was established with intravenous (IV) hydrocortisone and IV cellcept, with no impairment in graft function.

The clinical challenge was how to achieve adequate oral immunosuppression in a patient with only 80cm of small bowel, presuming drug absorption from the gastrointestinal tract is significantly reduced.

Animal studies demonstrate tacrolimus absorption is predominantly in the upper part of the small intestine[@b1] and the colon[@b2]. On review of the literature there are multiple cases which describe the use of tacrolimus in SBS, in both kidney[@b3] and other solid organ transplants[@b4]^,^ [@b5]. Interestingly, adequate tacrolimus levels can be achieved in the presence of a jejunostomy[@b4] and even in complete absence of small bowel[@b5].

We stopped cellcept, commenced oral tacrolimus (Prograf) and converted IV hydrocortisone to oral prednisolone. Tacrolimus absorption was monitored with blood trough levels (target trough 5-10 µg/L). The patient was initially commenced on Prograf 5mg BD (0.15mg/kg). The first trough level was 12µg/L. After a period of elevated levels the dose was reduced to a maintenance dose of 1.5mg BD and this remained stable for many months

7 months later he underwent surgery to reverse the ileostomy. After reversal surgery, tacrolimus trough levels rose to 14-18 µg/L and Prograf dose was reduced to 1mg BD, maintaining stable trough levels 4-8 µg/L. There were no concerns regarding medication compliance with this patient. It is noteworthy that with ileostomy reversal, trough levels rose significantly. This supports observations in animal studies of further tacrolimus absorption in the colon[@b2].

This case reminds us of the challenge of attaining adequate oral immunosuppression in renal transplant recipients who develop SBS. Tacrolimus can be used in this situation. Trough levels should be monitored and the dose adjusted in line with the surgery performed.
